Equity Tactical Top Picks Overview

  

Name

Name

Ticker

Ticker

UBS Rating*
CIO Preference**

UBS Rating*
CIO Preference**

Inception Date

Inception Date

Inception Price Local Currency

Inception Price Local Currency

Reference Number

Reference Number

Name

Baidu Sp ADR-A

Ticker

BIDU US

UBS Rating*
CIO Preference**

Buy | MP

Inception Date

21/01/2021

Inception Price Local Currency

251.91

Reference Number

210121-65409

Name

China Life Ins -H

Ticker

2628 HK

UBS Rating*
CIO Preference**

Buy

Inception Date

18/01/2021

Inception Price Local Currency

17.64

Reference Number

180121-65278

Name

Yum China Hld Rg

Ticker

YUMC US

UBS Rating*
CIO Preference**

Buy | MP

Inception Date

11/01/2021

Inception Price Local Currency

59.78

Reference Number

110121-65099

Name

Ascendas REIT

Ticker

AREIT SP

UBS Rating*
CIO Preference**

Neutral | MP

Inception Date

05/11/2020

Inception Price Local Currency

3.21

Reference Number

051120-63338

Name

Alibaba Health I Rg

Ticker

241 HK

UBS Rating*
CIO Preference**

Buy | MP

Inception Date

08/10/2020

Inception Price Local Currency

21.10

Reference Number

081020-62318

Name

Pharmaron Rg-H 144A-S

Ticker

3759 HK

UBS Rating*
CIO Preference**

Buy

Inception Date

03/09/2020

Inception Price Local Currency

105.40

Reference Number

030920-61319

Name

Name

Ticker

Ticker

UBS Rating*/
/IO Preference**

UBS Rating*/
/IO Preference**

Inception Date

Inception Date

Inception Price Local Currency

Inception Price Local Currency

Reference Number

Reference Number

Name

DocuSign Rg

Ticker

DOCU US

UBS Rating*/
/IO Preference**

Buy

Inception Date

11/01/2021

Inception Price Local Currency

240.96

Reference Number

110121-65098

Name

Lowe's Com Rg

Ticker

LOW US

UBS Rating*/
/IO Preference**

Buy | MP

Inception Date

11/01/2021

Inception Price Local Currency

166.32

Reference Number

110121-65100

Name

Microsoft Rg

Ticker

MSFT US

UBS Rating*/
/IO Preference**

Buy | MP 

Inception Date

12/10/2020

Inception Price Local Currency

221.40

Reference Number

121020-62398

Name

Alphab Rg-C-NV

Ticker

GOOG US

UBS Rating*/
/IO Preference**

Buy | MP

Inception Date

03/09/2020

Inception Price Local Currency

1,641.84

Reference Number

030920-61317

Name

NVIDIA Rg

Ticker

NVDA US

UBS Rating*/
/IO Preference**

Buy | MP

Inception Date

03/09/2020

Inception Price Local Currency

520.62

Reference Number

030920-61318

Name

Berkshire Hath Rg-B

Ticker

BRK/B US

UBS Rating*/
/IO Preference**

Buy

Inception Date

31/08/2020

Inception Price Local Currency

218.04

Reference Number

310820-61199

Name

Name

Ticker

Ticker

UBS Rating*
CIO Preference**

UBS Rating*
CIO Preference**

Inception Date

Inception Date

Inception Price Local Currency

Inception Price Local Currency

Reference Number

Reference Number

Name

Intl. Cons. Air Rg

Ticker

 IAG LN

UBS Rating*
CIO Preference**

Buy

Inception Date

07/12/2020

Inception Price Local Currency

1.67

Reference Number

071220-64222

Name

BP Rg 

Ticker

BP/ LN

UBS Rating*
CIO Preference**

Buy | MP

Inception Date

07/12/2020

Inception Price Local Currency

2.74

Reference Number

071220-64223

Name

Ferrari Rg

Ticker

RACE IM

UBS Rating*
CIO Preference**

Buy | MP

Inception Date

19/10/2020

Inception Price Local Currency

162.85

Reference Number

191020-62658

 

Disclosures

You may consider an investment in this product, if

You are an experienced investor familiar with equity securities and the equity markets in General.

You have an investment horizon that matches the specific equity in which you are investing. You also understand you may hold the investment for an indefinite period of time if the equity is halted or suspended indefinitely, or if illiquid market conditions prevent the sale of the instrument. You are prepared to accept capital loss by stop losing the position if the investment price moves in an unfavorable direction.

You are not over concentrated in the position (e.g. by asset class, market or issuer etc.).

You are prepared to assume the risks, including margin call, forced liquidation and interest rate / charges, that are related to margin investment if you acquire the position by financing. The loss can exceed the original investment amount and you will be liable for any resulting deficit and interest charged being accrued on your account.

You are aware that mark to market of the equities could place your capital at risk. You are prepared to accept the risks associated with equities as described herein, and including corporate actions such as 1) capital change – default resolution, divestiture, equity offerings, equity redemption, exchange offer, funged issue, rights offering, spin off, 2) corporate events – change in trading status, change in listing, class action, convert exercised, delisting, domicile change, round lot change, ticker symbol change, voting rights change, name change, change in trading currency, and 3) capital distributions – distributions, cash dividend, liquidation, stock dividend, stock split.

You are a Professional Investor in Hong Kong and / or an Accredited Investor in Singapore.

Summary of main product-specific benefits

Main benefit of equity investment is the potential for capital gain.

Some equity also has regular dividend payment, however dividend payment is not guaranteed.

Summary of main product-specific risks

The prices of securities fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities.

Equity investment may expose to various types of risk including (i.e. but not limited to) market risk, interest rate risk, currency risk and liquidity risk. Investor should consider carefully to determine if entering into the position is suitable for you in light of, among other things, your financial situation, need for liquidity, tax situation, and your other investments.

Additional Disclosures

Some of the ideas being mentioned in the presentation are listed in the oversea markets and their denominated currency may be different to your portfolio's denominated currency. Changes in the currency exchange rates may affect the value of your position (i.e. in accordance to your portfolio's denominated currency) and result in unpredictable losses or profits.

Tax Treatment

UBS does not provide tax or legal advice. You must verify the above and all other information provided in this presentation or otherwise, with your external tax and legal advisors. Please read in conjunction with the risk information at the end of the presentation.

Further Information

This product description is for information purposes only.

The Marketing Material gives general information about products only and that the client should refer to his Client Advisor as regards to suitability of a specific product.

The contents of this document have not been reviewed by any regulatory authority in Hong Kong or Singapore. Investors are advised to exercise caution in relation to any offer. If an Investor is in any doubt about any of the contents of this document, the Investor should obtain independent professional advice.

This document is communicated by UBS AG and/or its affilliates ("UBS") for the exclusive use of the party to whom UBS delivers this document. UBS may from time to time, as principal or agent, have positions in, or may buy or sell, or make a market in any securities, currencies, financial instruments or other assets underlying the transaction to which any term sheet, Information Memorandum, Prospectus, confirrmation or other documentation for the issue of the product or for which the transaction relates (collectively, the "Documentation"). UBS may provide investment banking and other services to and/or have officers who serve as directors of the companies referred to in the Documentation. UBS may pay or receive fees in connection with transactions of securities to or from third parties. Further information on any discount to the issue Level provided by UBS Investment Bank division to UBS Wealth Management division is available in the sales related information disclosure or other similar document for the securities, which may be provided by UBS Wealth Management division from time to time. UBS has policies and procedures designed to minimize the risk that officers and employees are influenced by any conflicting interest or duty and that confidential information is improperly disclosed or made available. The investor acknowledges that UBS may retain all or part of such fees.

UBS generally hedges its exposure under structured transactions, although it may elect not to hedge or to partially hedge any transaction. UBS’ hedging activity may be conducted through transactions in the underlying asset, index or instrument or in options, futures or other derivatives related to the underlying asset, index or instrument on publicly traded markets or otherwise, and may have an impact on the Level of the underlying asset. If a transaction is cash settled, UBS will generally unwind or offset any hedge it has for such transaction in close proximity to the relevant valuation time or period. In some cases, this activity may affect the value of the transaction.

Prospective investors should be aware that receipt of any payment (whether coupon payment, redemption amount or otherwise) and/or any securities by an investor in connection with the transaction is subject to the credit risk of the issuer of the securities (the "Issuer") or counterparty to the transaction (the "Counterparty"). Investors assume the risk that the Issuer or Counterparty will not be able to satisfy its obligations under the transaction. Except where specifically provided otherwise, the Issuer's or the Counterparty's obligations under the transaction will constitute general and unsecured contractual obligations of the Issuer or Counterparty, respectively, and such obligations will rank equally with all other unsecured contractual obligations of the Issuer or Counterparty, respectively, and any subsequent unsecured obligations of the Issuer or Counterparty, respectively. In the case of an insolvency of the Issuer or Counterparty, preferred liabilities of the Issuer or Counterparty, respectively, will have priority over unsecured obligations such as the transaction.

Any credit rating of the Issuer or the Counterparty stated in the Documentation reflects the independent opinion of the referenced rating agency as to the creditworthiness of the rated entity but is not a guarantee of credit quality of the Issuer or the Counterparty. Any downgrading of the credit ratings of the Issuer or Counterparty or their respective affiliates, by any rating agency could result in a reduction in the value of the product.

Structured transactions are complex and may involve a high risk of loss. Prior to entering into a transaction you should consult with your own independent legal, regulatory, tax, financial and accounting advisors to the extent you consider it necessary, and make your own investment, hedging and trading decisions (including decisions regarding the suitability of this transaction) based upon your own judgment and advice from those advisers you consider necessary. Save as otherwise expressly agreed, UBS is not acting as your financial adviser or fiduciary in any transaction.

This document is for information purposes only and has no regard to the specific investment objectives, financial situations or particular needs of any specific recipient. Any charts and scenarios set out in this document are for illustrative purposes only. No representation or warranty, either express or implied is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the developments referred to in this document.

The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The information and any opinions expressed in this document are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. UBS is under no obligation to update or keep current the information contained in this document.

This document does not constitute and should not be construed as an offer, recommendation or solicitation to conclude a transaction nor should it be treated as giving investment advice. The terms of the transaction will be exclusively subject to the detailed provisions, including any risk considerations, contained in the Documentation. Any investment or any other decisions should not be made based solely on this material. Neither UBS AG nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this material.

UBS specifically prohibits the redistribution or reproduction of this document and any of the material in this document in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect.

No action has been or will be taken in any jurisdiction that would permit a public offering of the securities described in this document, save where explicitly stated in the Documentation. Where applicable, the securities must be sold in accordance with all applicable selling restrictions in the jurisdictions in which they are sold.

Not for distribution in the United States or to U.S. persons
© UBS 2021. All rights reserved.

Country specific disclaimers

Any offering material term sheet, research report, other product or service documentation or any other information (the "Material") made available was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. The Material, where provided, was provided for your information only and is not to be further distributed in whole or in part in or into your jurisdiction without the consent of UBS. The Material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or products or futures contracts). The Material is neither an offer nor a solicitation to enter into any transaction or contract (including future contracts) nor is it an offer to buy or to sell any securities or products. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt.

Any and all advice provided on and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you.

Any offering material, term sheet, research report, other product or service documentation or any other information (the "Material") made available was done so as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. The Material, where provided, was provided for your information only and is not to be further distributed in whole or in part in or into your jurisdiction without the consent of UBS. The Material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. UBS has not, by virtue of the Material, made available, issued any invitation to subscribe for or to purchase any investment (including securities or derivatives products). The Material is neither an offer nor a solicitation to enter into any transaction or contract (including future contracts) nor is it an offer to buy or to sell any securities or derivatives products. The relevant investments will be subject to restrictions and obligations on transfer as set forth in the Material, and by receiving the Material you undertake to comply fully with such restrictions and obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt.

Any and all advice provided and/or trades executed by UBS pursuant to the Material will only have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you.

Hong Kong & Singapore Private Clients

PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE PROCEEDING. BY UTILIZING THE WEBSITE AND PAGES THEREOF LOCATED AT WWW.UBS.COM ("WEBSITE"), YOU ACKNOWLEDGE THAT YOU HAVE READ THESE TERMS AS WELL AS THE GLOBAL TERMS OF USE (collectively "TERMS") AND THAT YOU AGREE TO BE BOUND BY THEM. IF YOU DO NOT AGREE TO ALL OF THE TERMS OF THIS AGREEMENT, YOU ARE NOT AN AUTHORIZED USER OF THESE SERVICES AND YOU SHOULD NOT USE THIS WEBSITE.

Investor status

  • Confirm that I meet the requirements to qualify as:
  • a "Professional Investor” in accordance with Section 1 of Part 1 of Schedule 1 of the Securities and Futures Ordinance (Cap 571 of the Law of Hong Kong) and as a “Private Banking Customer” as defined in the circular issued by the Hong Kong Monetary Authority on 12 June 2012; and/ or
  • an "accredited investor" or "institutional investor" as defined in the Securities and Futures Act (Chapter 289) of Singapore

Disclaimer

Content provided on “as is” and “as available” basis

  • Confirm my understanding that the materials, information or reports published, distributed or otherwise made available on the UBS Website
    (a) are published for information purposes only and are subject to change at any time without notice;
    (b) have been created without any regard to the specific investment objectives, financial situation or particular needs of any specific recipient and should not be construed as a solicitation, offer or recommendation or advice to buy or sell any securities, investment or other financial instruments, to effect any transactions or to conclude any legal act of any kind whatsoever.
Reset